☆ 4.7 Article

A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

CLINICAL CANCER RESEARCH (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Nicholas Turner et al.

Summary: The IPATunity130 Cohort B study investigated the use of ipatasertib-paclitaxel in HR+ breast cancer patients with PI3K pathway mutations. The results showed that adding ipatasertib to paclitaxel did not improve efficacy in these patients.

BREAST CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Oncology

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Brian W. Labadie et al.

Summary: This article summarizes the safety data of the PARP inhibitor rucaparib for the treatment of metastatic castration-resistant prostate cancer and provides guidelines for managing treatment-emergent adverse events. The study found that the adverse events observed with rucaparib were consistent with other PARP inhibitors, with gastrointestinal events, asthenia/fatigue, and anemia being the most common. Most adverse events were self-limiting and did not require treatment modification or interruption.

CANCER MANAGEMENT AND RESEARCH (2022)

添加到收藏夹

Article Oncology

Activation of the AKT pathway and outcomes in patients (pts) treated with or without ipatasertib (ipat) in metastatic castration-resistant prostate cancer (mCRPC): Next-generation sequencing (NGS) data from the phase III IPATential150 trial.

Christopher Sweeney et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib

Mingxiang Liao et al.

Summary: This article provides a comprehensive review of the clinical pharmacokinetics, pharmacodynamics, drug-drug interactions, effects of intrinsic and extrinsic factors, and exposure-response relationships of rucaparib. Rucaparib has a manageable safety profile, with fatigue and nausea being the most common adverse events. It has moderate oral bioavailability and can be taken with or without food. A dose-dependent effect on selected clinical efficacy and safety endpoints was observed in patients.

CLINICAL PHARMACOKINETICS (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Mitigating ipatasertib-induced glucose increase through dose and meal timing modifications

Dhruvitkumar S. Sutaria et al.

Summary: This study evaluated the glucose changes in mCRPC patients treated with a combination of Ipatasertib, prednisone, and abiraterone. The results showed that this combination increased blood glucose levels, but administering it in the evening reduced peak glucose levels and improved the percentage of time within a certain range.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Meeting Abstract Oncology

PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.

Johann S. De Bono et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)

C. N. Sternberg et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Shannon N. Westin et al.

Summary: This study aimed to confirm the recommended phase II dose for the combination of olaparib and capivasertib in multiple cancers, and evaluate molecular markers of response and resistance. Promising responses, especially in endometrial cancer, were observed among the 38 enrolled patients. Therapy resistance was associated with specific signaling pathways and metabolic factors.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients

Kenta Yoshida et al.

Summary: A population pharmacokinetic study was conducted to characterize the pharmacokinetic profiles of ipatasertib and its metabolite M1. Covariate effects of ipatasertib include decreased oral clearance with increasing age and coadministration of abiraterone, as well as decreased bioavailability with increasing weight. For M1, increased body weight was associated with an increase in both peripheral distribution volume and intercompartmental clearance. Coadministration of abiraterone was estimated to increase M1 exposure by 61% at steady state.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Review Oncology

Role of Akt Activation in PARP Inhibitor Resistance in Cancer

Ferenc Gallyas et al.

CANCERS (2020)

添加到收藏夹

Article Medicine, General & Internal

Olaparib for Metastatic Castration-Resistant Prostate Cancer

J. de Bono et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers

Timothy A. Yap et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Oncology

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

Wassim Abida et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Urology & Nephrology

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

Philipp Nuhn et al.

EUROPEAN UROLOGY (2019)

添加到收藏夹

Article Oncology

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Johann S. de Bono et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Panagiotis A. Konstantinopoulos et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

M R Smith et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Management of toxicity to isoform α-specific PI3K inhibitors

S. E. Nunnery et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Medicine, General & Internal

Metastatic Prostate Cancer

Oliver Sartor et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

添加到收藏夹

Article Oncology

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer

U. A. Matulonis et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Cristina Saura et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors

Charles-Andre Philip et al.

BMC CANCER (2017)

添加到收藏夹

Article Oncology

Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways

Yingmei Wang et al.

GYNECOLOGIC ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

J. Mateo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Yasir H. Ibrahim et al.

CANCER DISCOVERY (2012)

添加到收藏夹

Article Cell Biology

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations

Konstantin J. Dedes et al.

CELL CYCLE (2011)

添加到收藏夹

Article Medicine, General & Internal

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt et al.

LANCET (2010)

添加到收藏夹

Article Medicine, General & Internal

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.

Peter C. Fong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

添加到收藏夹

Article Oncology

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

S Oudard et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

添加到收藏夹

Article Medicine, General & Internal

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

DP Petrylak et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

添加到收藏夹

Article Medicine, General & Internal

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

IF Tannock et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

添加到收藏夹

Article Oncology

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

M Esteller et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.